The diagnosis of multiple system atrophy

Geser, Felix; Wenning, Gregor K.

doi:10.1007/s00415-006-3002-x

Cited by 6 publications

(5 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Braak et al, the neurodegenerative process in Parkinson's disease also affects other CNS structures than those contained in the corticostriatal, nigrostriatal or olivonigral systems 1-4. Other studies published several years ago suggest that in a relatively high percentage of patients suffering from neurodegenerative diseases, both the cortex and peripheral nerve system are affected. 1,5,6,7 Parkinson's disease is where this involvement is most frequently documented.…”

Section: Introductionmentioning

confidence: 99%

Peripheral nerve involvement and severity of motor disorder in Parkinson\'s disease: a correlational study

Chovancová¹,

Kaňovský²,

Dufek³

et al. 2009

BIOMED PAP

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Peripheral nerve involvement and severity of motor disorder in Parkinson\'s disease: a correlational study

Chovancová¹,

Kaňovský²,

Dufek³

et al. 2009

BIOMED PAP

View full text Add to dashboard Cite

“…Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years 1. Clinically, MSA is dominated by autonomic failure, which may be associated with either levodopa ( L ‐dopa)‐unresponsive Parkinsonism in 80% of cases (MSA‐P subtype) or with cerebellar ataxia in 20% of cases (MSA‐C subtype) 2.…”

mentioning

confidence: 99%

Autonomic dysfunction in different subtypes of multiple system atrophy

Schmidt

Herting²,

Prieur

et al. 2008

Movement Disorders

View full text Add to dashboard Cite

Multiple system atrophy (MSA) can clinically be divided into the cerebellar (MSA-C) and the parkinsonian (MSA-P) variant. However, till now, it is unknown whether autonomic dysfunction in these two entities differs regarding severity and profile. We compared the pattern of autonomic dysfunction in 12 patients with MSA-C and 26 with MSA-P in comparison with 27 age- and sex-matched healthy controls using a standard battery of autonomic function tests and a structured anamnesis of the autonomic nervous system. MSA-P patients complained significantly more often about the symptoms of autonomic dysfunctions than MSA-C patients, especially regarding vasomotor, secretomotor, and gastrointestinal subsystems. However, regarding cardiovascular, sudomotor pupil, urogenital, and sleep subsystems, there were no significant quantitative or qualitative differences as analyzed by autonomic anamnesis and testing. Our results suggest that there are only minor differences in the pattern of autonomic dysfunction between the two clinical MSA phenotypes.

show abstract

“…Our patient fulfilled the clinical consensus criteria for possible multiple system atrophy [2] since she presented with a levodopa unresponsive parkinsonism, pyramidal tract signs, and severe autonomic dysfunction. Nigral degeneration with brain iron accumulation appears very unlikely because of the age at onset of symptoms.…”

Section: Discussionmentioning

confidence: 99%